Abstract | Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE, the absence of universally agreed clinical trial end points, and the paucity of validated therapeutic targets have, historically, contributed to a lack of novel treatments for SLE. However, in 2011, a therapeutic monoclonal antibody that neutralizes the cytokine TNF ligand superfamily member 13B (also known as B-cell-activating factor of the TNF family [BAFF]), belimumab, became the first targeted therapy for SLE to have efficacy in a randomized clinical trial. Because of its specificity, the efficacy of belimumab provides an opportunity to increase understanding of SLE pathophysiology. Although belimumab depletes B cells, this effect is not as powerful as that of other B-cell-directed therapies that have not been proven efficacious in randomized clinical trials. In this article, therefore, we review results suggesting that neutralizing BAFF can have effects on the immune system other than depletion of B cells. We also identify aspects of the BAFF system for which data in relation to SLE are still missing, and we suggest studies to investigate the pathogenesis of SLE and ways to refine anti-BAFF therapies. The role of a related cytokine, TNF ligand superfamily member 13 (also known as a proliferation-inducing ligand [APRIL]) in SLE is much less well understood, and hence this review focuses on BAFF.
Introduction
Systemic lupus erythematosus (SLE) is an idiopathic, systemic autoimmune disease. 1 Although the cause of this disease is unclear, research over the past two decades has provided new insights into its patho genesis. One breakthrough was the discovery, in 1999, of a crucial Bcell survival factor, TNF ligand super family member 13B (also known as B cellactivating factor of the TNF family [BAFF] , Blymphocyte stimu lator [BLyS] , zTNF4, THANK and TALL1), 2 which has an important role in autoimmunity, and in particular in SLE pathogenesis. 3, 4 In 2011, belimumab, a mono clonal antibody targeting human BAFF, was shown in ran domized clinical trials to be efficacious in a subset of patients with SLE and has now become the first approved targeted therapy for SLE. 5, 6 As a consequence, clinical inhibition of BAFF has generated substantial interest and similar biologic agents are being tested in clinical trials. The efficacy of a specific antiBAFF treatment demonstrated that SLE is not exclusively a Tcellmediated disease and has renewed the scientific community's interest in the pathogenesis of SLE.
Clinical trials and post hoc analysis of data obtained from belimumabtreated patients with SLE have pro vided useful information about BAFF and a related cytokine, TNF ligand superfamily member 13 (also known as a proliferationinducing ligand [APRIL] ). Data suggest that mechanisms other than Bcell depletion are affected during responses to treatment with belimumab. In addition, the deregulation of BAFF and APRIL is found in specific subsets of patients with SLE. 7 The 'BAFF/APRIL system' and the innate immune system coordinate in regulating the innate activation of B cells, and seem to be defective in a mouse model of SLE in which BAFF is overexpressed. 8 Several receptors and various biochemical forms of the ligands exist in the BAFF/APRIL system, [9] [10] [11] but further work is required to elucidate their respective contributions to the patho genesis and phenotype of SLE. In this article, we review the BAFF/APRIL system and highlight new discoveries that are relevant to the improvement of SLE management and that might lead to therapeutic innovation. In light of an ongoing debate about the role of APRIL in SLE, we have predominant ly focused this Review on BAFF.
The BAFF/APRIL system
Two ligands, BAFF and APRIL, and three receptors, TNF receptor superfamily member 13C (also known as BAFF receptor [BAFFR] or BLyS receptor 3 [BR3]), TNF receptor superfamily member 17 (also known as Bcell maturation antigen [BCMA] ) and TNF receptor superfamily member 13B (also known as trans membrane activator and cyclophilin ligand interactor [TACI] ) form the backbone of the BAFF/APRIL system. BAFF and APRIL can both interact with BCMA and TACI, whereas BAFF is the sole ligand for BAFFR (reviewed previously 12 ; Figure 1 ). BAFFR is essential for both sur vival and maturation of immature B cells, whereas TACI is critical for Tcellindependent responses of B cells to type I and type II antigens, negative regulation of the Bcell compartment and classswitch recombination of B cells (reviewed previously 13 ). BCMA is expressed by plasmablasts and plasma cells, and promotes plasma cell survival.
BAFF and APRIL are produced by myeloid cells, pre dominantly by macrophages, neutrophils and dendri tic cells (DCs), and also by radiationresistant stromal cells.
14 Lymphoid cells, including B cells and activated T cells, can also produce BAFF and APRIL. Finally, Toll like receptor 9 (TLR9)activated plasmacytoid DCs and IL2activated natural killer cells also produce BAFF (reviewed previously 12 ).
Key points
■ TNF ligand superfamily member 13B (also known as B cell-activating factor of the TNF family [BAFF] ) and TNF ligand superfamily member 13 (also known as a proliferation-inducing ligand [APRIL] ) are important modulators of autoimmunity ■ Data indicate that alteration of the BAFF/APRIL system affects the capacity of the innate immune system to regulate B-cell activation ■ BAFF and type I interferons function together in systemic lupus erythematosus (SLE) pathogenesis in both a Toll-like receptor-dependent and independent manner ■ Defining the clinical manifestations of disease related to alterations of the BAFF/APRIL system might help to stratify patients with SLE into subgroups that are more likely to benefit from anti-BAFF treatment ■ Differences in the molecular forms of BAFF might affect the efficacy of BAFF-specific therapies BAFF and APRIL are type II transmembrane pro teins. 3, 15, 16 BAFF can also be processed into a soluble cytokine after cleavage at a furin protease site, 3, 15 whereas APRIL is mainly produced in a soluble form. 16, 17 Two exceptions, which are membrane bound, are the APRILδ isoform, first identified in malignant Bcell tumours, 18 and TWEPRIL, a hybrid protein of APRIL and TNF ligand superfamily member 12 (also known as TNF related weak inducer of apoptosis [TWEAK] ). 19 The receptorbinding domain of BAFF is trimeric; 20 however, 20 BAFF trimers can assemble into a BAFF 60mer. 10, 11 Furthermore, BAFF and APRIL can assemble as BAFF-APRIL heterotrimers of undefined stoichio metries, which have been detected in the serum of patients with rheumatic diseases (Figure 2 ). Recombinant BAFF-APRIL heterotrimers are biologically active, albeit less than BAFF or APRIL homotrimers. 21, 22 Heterotrimers of various compositions might be differentially susceptible to BAFFtargeting therapies.
Mice expressing BAFF with a mutated furin cl eavage site have a phenotype similar to Baff -/-(Tnfsf13b -/-) mice, suggesting that membranebound BAFF cannot sub stitute for soluble BAFF. 23 However, when treated with soluble BAFF, B cells from the BAFF furin mutant mice became more similar to B cells from wild type mice than to B cells from Baff -/-mice that were also treated with soluble BAFF. 23 These results suggest a twostep process in BAFFmediated Bcell maturation. First, soluble BAFF promotes Bcell survival by activat ing BAFFR, and then the Bcell phenotype is modu lated by membranebound BAFF signals, possibly by activating TACI. 23 Human BAFF is a 285 aminoacidlong protein with two potential Nglycosylation sites. 24 Because some enzymelinked immunosorbent assays (ELISAs) detect only unglycosylated BAFF, whereas other ELISAs detect both unglycosylated and glycosylated BAFF, post translational Nglycosylation status could explain the failure to consistently associate disease activity with serum BAFF concentrations. 24 Alternative splice vari ants of BAFF, particularly ∆BAFF, might have an impor tant role in SLE pathogenesis. [25] [26] [27] [28] Mouse ∆BAFF decreases the bioactivity and release of fulllength BAFF by associ ating with BAFF and forming inactive hetero trimers. 26 In mice, BAFF and ∆BAFF can both modulate B1 B cells. 25, 26 BAFFϕ is a nonfunctional isoform identified in human cell lines. 26 Although currently unknown, it is possible that antiBAFF biologic agents might differ in their ability to bind and neutralize the various human BAFF isoforms or glycosylation variants.
The BAFF/APRIL system in SLE BAFF is necessary for Bcell maturation and survival. Mice genetically deficient in BAFF lack mature B cells and are immunodeficient, 29 whereas mice that over produce BAFF have high numbers of mature B cells and antibodies, including autoantibodies, and develop an autoimmune disease similar to SLE in humans. 2 Together with the observation that BAFF blockade decreased symptoms of SLE in mouse models, 30 -/-) mice, both strains had mild kidney immunopathology, 33 suggesting that blocking both BAFF and APRIL in patients with SLE might not be benefi cial and could even increase the risk of toxicity. Further supporting this idea, a phase II/III clinical trial of the chimeric recombinant fusion protein atacicept (com bining TACI with an immunoglobulin constant region), which neutralizes BAFF, APRIL and BAFF-APRIL hetero trimers in patients with active lupus nephritis, was stopped because of serum IgG depletion and an increased rate of infections. 34 
Belimumab
Belimumab is a fully human recombinant monoclo nal IgG 1 λ antibody that impairs Bcell survival by tar geting soluble, not membranebound, human BAFF. 35 The addition of belimumab to standard therapy has been studied in two multicentre, doubleblind, placebo controlled, randomized phase III clinical trials in patients with SLE, cumulatively examining 1,684 patients for up to 76 weeks. 5, 6 Various scoring systems are used to evaluate disease activity in human SLE clini cal trials, such as SLE disease activity index (SLEDAI), British isles lupus assessment group (BILAG) or SLE res ponder index (SRI).
36-38 These composite scores of clini cal and laboratory features enable scaled assess ment of disease activity at a single time point. Patients with active SLE who tested positive for SLEassociated antibodies benefited from belimumab compared with placebo with respect to disease activity (SRI) and healthrelated quality of life, with a satisfactory drug safety profile. 5, 6, 39, 40 Belimumab therapy was associated with reduced autoantibody levels and normalized low complement levels, 41 and in post hoc analysis, patients with high disease activity (Safety Of Oestrogens In Lupus Erythematosus National Assessment [SELENA] SLEDAI), high antidoublestranded DNA antibody and low complement levels at baseline had superior treat ment responses to belimumab. 42 Belimumab therapy also reduced the number of circulating naive B cells, activated B cells and plasma cells, but did not reduce the number of circulating memory B cells or T cells. 41 No effects on antibody responses to previous pneumococ cal, tetanus or influenza immunizations were detected after 1 year of treatment, consistent with a preserved memory Bcell compartment.
43
BAFF and APRIL as biomarkers of SLE In comparison with serum from healthy individuals, serum concentrations of BAFF and APRIL are higher in patients with autoimmune diseases, such as SLE, pri mary Sjögren's syndrome and rheumatoid arthritis (reviewed previously 13 ). Whether serum BAFF or APRIL can be used as a biomarker in SLE has been a matter of debate over the past decade, with some studies reporting corre lations between serum BAFF and APRIL concentra tions and overall disease ac tivity, 44-47 whereas others found no such correlations.
41,47-50 Petri et al. 51 showed, using multi variate analysis, that elevated baseline serum BAFF concentration (≥2 ng/ml) was predictive of moderatetosevere SLE flares in patients receiv ing the standard therapy, prednisone with antimalarial (hydroxychloroquine) or immunosuppressive drugs (methotrexate, mycophenolate mofetil and azathio prine). This association is supported by another study, BAFF, B-cell-activating factor of the TNF family (also known as TNF ligand superfamily member 13B); BAFF-R, BAFF receptor (also known as TNF receptor superfamily member 13C); BCMA, B-cell maturation antigen (also known as TNF receptor superfamily member 17); HSPG, heparan sulphate proteoglycans; SLE, systemic lupus erythematosus; TACI, transmembrane activator and cyclophilin ligand interactor (also known as TNF receptor superfamily member 13B); TWEAK, TNF-related weak inducer of apoptosis (also known as TNF ligand superfamily member 12); TWE-PRIL, a hybrid of TWEAK and APRIL.
in which a high serum BAFF concentration was associ ated with flares of SLE disease activity (assessed by the BILAG score) after rituximab treatment. 52 However, in our study, 7 among others, no significant association between serum BAFF concentration and disease activity (assessed using SLEDAI2k) was found. Moreover, in the belimumab phase III clinical trials, baseline serum BAFF concentration was not found to be predictive of outcome in either antiBAFF or controltreated patients. 41 These discrepancies might be caused by differences in assay sensitivity, disease activity scores or study populations. However, serum BAFF and APRIL concentrations might not accurately reflect total BAFF production or, in the case of APRIL (which binds proteoglycans), the concen tration of the active cytokine in tissues. Urinary excretion of cytokines, for example, might reduce serum concen tration in patients with renal disease, suggesting that the measurement of BAFF and APRIL in urine should be investigated by SLE researchers. 53 Perhaps the failure to reliably show an association between disease activity and the concentration of a cytokine known to be involved in the pathogenesis of SLE means that the measurement of disease activity requires reexamination. Moreover, given that post hoc analysis of clinical trial data revealed that BAFF inhibi tion was most effective in patients with active disease and high serum autoantibody titres, 42 this subset of SLE patients might be best suited for analysis of clinical associations of BAFF and APRIL expression. We could, therefore, study SLE patient subsets, defined according to specific clinical or immunological phenotypes.
SLE clinical subsets
Some studies measuring cytokines in patients with SLE have focused on SLE subsets rather than over all dis ease activity measured with composite indices of dis ease activity. [54] [55] [56] [57] [58] [59] [60] We showed that serum BAFF and APRIL concentrations, although not correlating with a composite measure of disease activity (SLEDAI2k), were increased and decreased, respectively, in sub sets of patients with SLE who also had renal or central nervous system (CNS) pathology. 7 These data are sup ported by findings from mouse studies, in which sepa rate pathways that regulate autoimmunity, inflammation and renal damage led to differentiated phenotypes of disease. 61, 62 Combining different genetic loci such as Sle3 and Sle5, with or without Sle1, leads to differentiated phenotypes in lupusprone mice. 62 If distinct immuno logical pathways are activated in humans with differ ent disease manifes tations, then general bio markers for SLE might not exist. Some subsets of patients with SLE might, however, benefit from therapies targeting these pathways. The identification of reliable biomarkers for these subsets would be useful as a tool for the selec tion of therapy. Serum BAFF, for example, is increased in patients with CNS or renal pathology, therefore, these patients might benefit from antiBAFF therapy. 7 Although patients with severe CNS manifestations or severe lupus nephritis were excluded from two phase III clinical trials of belimumab, 5, 6 post hoc pooled analysis suggested that belimumab might be an effective treat ment for patients with SLE and renal involvement. 63 Also, in the subset of SLE patients without renal disease activity at baseline, those treated with belimumab had less renal involvement than patients given placebo. 64 Further research is needed to investigate the accuracy of using serum BAFF and APRIL measurements to predict SLE phenotype, and therapeutic responses in patients within the different subgroups.
Ethnicity and polymorphisms
Substantial ethnic variation in the prevalence and charac teristics of SLE exists. 65, 66 Asian, Indigenous Aus tralian and African patients with SLE suffer from more severe disease compared with white people. 7, [65] [66] [67] [68] In one report, serum BAFF or APRIL concentration was not associated with Asian ethnicity; 7 however, African American patients with SLE had higher serum BAFF concentrations than white American patients with SLE, although not significantly after multivariate analysis. 69 By contrast, increased serum BAFF concentration was asso ciated with an increase in the SLEDAI in white American patients, but not in African American patients. 69 Further research is needed to understand how particular ethnic subgroups respond to antiBAFF therapies.
Future research could focus on BAFF and APRIL single nucleotide polymorphisms (SNPs). Several SNPs have been identified in the promoter, coding and untranslated regions of TNFSF13B (the human BAFF gene), but in most studies no significant association with SLE susceptibility has been found. 70, 71 Only one study reported an association (in Egyptian patients with SLE) between disease susceptibility and 871C>T and 2701T>A SNPs in the BAFF promoter region.
72 TNFSF13B pro moter SNPs were not significantly associated with symp toms of SLE. Monocytes from healthy individuals with the 871T allele had a significant increase in BAFF mRNA compared with monocytes from healthy individuals without the 871T allele. 70 SNPs have also been found in TNFSF13 (the human APRIL gene), including Gly67Arg, which was signifi cantly associated with SLE susceptibility in Japanese patients. 73 Another study showed a possible associa tion between Gly67Arg and SLE susceptibility in African American and Hispanic people, but not in white American people. 74 Additionally, the c.199Ac.287G (67Arg96Ser) SNP was reported to be a protective haplotype whereas the c.199Gc.287A (67Gly96Asn) haplotype was associated with disease susceptibility in Japanese patients with SLE. 75 In line with its protective effect, the protective haplotype 67Arg96Ser decreased soluble APRIL secretion in transfection experiments. 76 BAFF and APRIL receptors in SLE Exacerbation of disease in lupusprone BCMAdeficient mice (MRLFas lpr /J.Tnfrsf17 -/-and Nba2.Tnfrsf17
-/-mice), suggests that BCMA has a direct or indirect negative regulatory role. 77 In these mouse models, exacerbation of disease might occur by abnormal sig nalling of BAFF or APRIL through TACI or BAFFR in the absence of BCMA. Compared with wildtype and singlemutant control strains, BCMAdeficient lupus prone mice have more mature B cells and plasma cells in secondary lymphoid organs, more serum auto antibodies and BAFF, and more immune complex deposition in the kidneys. 77 An increase in the number of BAFF producing cells, such as DCs and macrophages, was also detected in these mice. 77 BCMA signalling might have an indirect regulatory role in the homeostasis of BAFF producing cells, because BCMA was not expressed by splenic DCs in all mouse strains in this study (MRL Fas lpr /J, Tnfrsf17 -/-, MRLFas lpr /J.Tnfrsf17 -/-and wild type mice). 77 Jacob et al. 78 showed that the deletion of BAFFR alone, which leads to profound Bcell deple tion, or of BCMA or TACI alone, did not protect against SLElike disease in NZM lupusprone mice. These data suggest that, unlike BAFFoverexpressing transgenic mice, 79 T cells might have an important role in the pathogenesis of NZM lupusprone mice. 78 The reticulon4 receptor (also known as the Nogo66 receptor [NgR]), a novel BAFF receptor that has not been confirmed by other laboratories, is expressed on neurons and astrocytes, and has been shown to mediate negative effects on neuron outgrowth via transducing BAFF signalling. 9 Whether BAFF signalling through NgR is relevant to the pathogenesis of SLE in the CNS is not known. We found that subsets of patients with SLE and CNS pathology had substantially more serum BAFF and less serum APRIL than patients with SLE and no CNS pathology. 7 BAFF and APRIL production by astrocytes has also been reported in patients with multiple sclerosis, another autoimmune disease affect ing the CNS. 27, 80 In the cerebrospinal fluid of patients with SLE, BAFF and APRIL were significantly higher than in cerebrospinal fluid from healthy individuals. 81 In patients with SLE, BAFF and APRIL found in the CNS might be locally produced by astrocytes, or immi grant immune cells, or it might derive from systemic cytokine production that might cross the blood-brain barrier. NgR expression in the CNS might explain clini cal associations between BAFF expression and CNS pathology in patients with SLE, but this remains to be confirmed. Whether APRIL can also interact with NgR is not known.
BAFF, TLR cross-talk and IFN signatures
Type I interferons, and particularly IFNα, are thought to have a major role in SLE pathogenesis. SLE is charac terized by increased expression of IFNαinduced genes, referred to as the IFNα signature, in peripheral blood mononuclear cells and in target organs, such as the kidneys. 54, 82, 83 In some studies, serum IFNα con centrations and IFNinduced genes positively correlate with SLE disease activity (measured by SLEDAI).
82,84
IFNG expression is also increased in SLE, 60 and higher serum IFNγ concentrations have been reported in patients with SLE compared with healthy indivi duals. 85 Plasmacytoid DCs are the major source of IFNα pro duced in response to viruses and bacteria (reviewed previously 86 ). Activation of endosomal TLR7 and TLR9 by their respective agonists, singlestranded RNA and unmethylated CpGrich DNA, transduces signals through myeloid differentiation primary response pro tein MyD88 (MyD88) and upregulates IFNα expression. In SLE, antibody-nucleic acid immune complexes, for example RNA or DNA from necrotic or apoptotic cells, 87 are suggested to be bound by immuno globulin γ Fc region receptor IIa (FcγRIIa) and internalized by plasma cytoid DCs in the form of autoimmune complexes, sub sequently activating endosomal TLRs and upregulating IFNα production (Figure 3 ). 86, 88 Several studies indicate that interferons induce BAFF expression: IFNα upregulates BAFF expression by mouse macrophages; 89 IFNα and IFNγ both upregu late BAFF and APRIL expression by human DCs; 90 and IFNα and IFNγ can upregulate BAFF expression by human monocytes. 90 In response to IFNγ, more BAFF was produced by monocytes from patients with SLE than by monocytes from healthy donors. 91 In a phase Ia (6), possibly contributing to the mechanism that terminates the short-lived antibody response of activated innate B cells. This mechanism is defective in BAFF-overexpressing transgenic mice (7; Box 1). Abbreviations: BAFF, B-cell-activating factor of the TNF family (also known as TNF ligand superfamily member 13B); BAFF-R, BAFF receptor (also known as TNF receptor superfamily member 13C); BCMA, B-cell maturation antigen (also known as TNF receptor superfamily member 17); DC, dendritic cell; FasL, Fas ligand; FcγRIIa, immunoglobulin γ Fc region receptor IIa; LPS, lipopolysaccharide; MyD88, myeloid differentiation primary response protein MyD88; MZ, marginal zone; ssRNA, single-stranded RNA; TACI, transmembrane activator and cyclophilin ligand interactor (also known as TNF receptor superfamily member 13B); TLR4, Toll-like receptor 4.
IFN-α increases BAFF production (3). BAFF interacts with receptors on B cells (4). Excess BAFF can increase autoreactive B-cell survival, driving autoimmunity (5). TLR4 and TACI signalling cooperate to commit MZ B cells to apoptosis via induction of Fas and FasL
clinical trial of patients with SLE treated with an anti IFNα monoclonal antibody, BAFF mRNA expres sion in whole blood was suppressed. 92 Strikingly, in NZM lupusprone mice, BAFF deficiency prevented glomerulo nephritis and clinical disease in response to IFNα treatment. 93 The activity of IFNα in serum from patients with SLE positively correlated with serum BAFF concentrations. 69 Moreover, we demonstrated a regula tory feedback loop between TLR7 or TLR9 and TACI in BAFF transgenic mice, 79 and cooperation between TACI and TLR signalling in Fasinduced apoptosis, a mechanism that is defective in these mice (Box 1). 8 Collectively, these mouse and human studies of SLE pathogenesis suggest that the roles of BAFF and IFNα are closely linked (Figure 3) . One study showed that, through an IFNαdependent pathway, monocytes from healthy individuals can differentiate into DCs when cul tured with serum from patients with SLE (SLEDCs), and this induction of DC differentiation also correlated with the SLE disease activity (measured by SLEDAI). 94 SLEDCs can induce Bcell proliferation and plasma blast differentiation. 95 Interestingly, DCs differen tiated from monocytes, from healthy individuals, and cul tured with IFNα plus granulo cyte macrophage colony stimulating factor (IFNDCs), phenotypically differ from SLEDCs. One of the main differences is that IgG secretion was enhanced (dependent on BAFF) by SLEDCs but not IFNDCs. 95 
Therapeutic innovation
Although known antiBAFF biologic agents bind to soluble or membranebound BAFF, the speci ficity for homotrimer, heterotrimer and 60mer forms is unclear. Belimumab targets only soluble human BAFF. 35 Tabalumab (also known as LY2127399), a fullyhuman IgG 4 monoclonal antibody, neutralizes both soluble and membranebound human BAFF. 96 Blisibimod (also known as A623) is a fusion polypeptide protein that targets human BAFF and binds to both soluble and membranebound BAFF in mouse models of SLE and rheumatoid arthritis. 97 Major differences between BAFF trimer and 60mer forms have been investigated using mouse models; however, in humans, these forms of BAFF have not been studied in detail and the 60mer has not been described. In primary B cells isolated from mice, TACI is activated by the BAFF 60mer, but not the BAFF trimer. 20 TACI interacts with MyD88, a signalling adaptor critical for the development of BAFFmediated autoimmunity in mice, 79 suggesting that TACI, and hence the BAFF 60mer, might be important in regulating autoimmune disease. One of the major unanswered questions is whether human BAFF exists in both trimer and 60mer forms, and what functions the different forms might have in disease. Indeed, if the BAFF 60mer is the active form in humans, activeformspecific antiBAFF therapies might be devel oped by neutralizing only the active BAFF 60mer, or by therapeutically disrupting the active 60mer into the less active trimer (Figure 2 ). The BAFF 60mer is not an established molecular form of BAFF in vivo and has yet to be characterized in mice and humans.
If findings on the reduced bioactivity of recombinant BAFF-APRIL heterotrimers apply to the native hetero trimer, heterotrimer formation could have a role in determining BAFF or APRIL activity in vivo. Analysis performed on a small cohort of 36 patients with SLE showed a nonsignificant trend towards a positive corre lation between serum BAFF-APRIL heterotrimer con centration and disease activity (measured by SLEDAI). 21 If supported by larger longitudinal, prospective studies, these data could be interpreted to mean either that hetero trimer formation drives speci fic pathogenic signals or that it reflects the action of a negative feedback loop without which the pathology is more severe (Figure 2 ). Whether heterotrimer formation occurs through de novo assembly of monomers in a cell producing both BAFF and APRIL, or whether homo trimers equilibrate into heterotrimers after synthesis and release is not known. However, hetero trimers can be predicted not to form 60mers. BAFF contains a loop sequence (the 'flap') that protrudes out of the monomer and hooks to the flap of BAFF in adjacent trimers. 10 Size analyses of recom binant BAFF 60mers, showed some BAFF trimers in addition to the 60mer, but no 6mer or 9mer (etc.) inter mediates, 11 suggesting that flap-flap interactions are weak and are probably only important when they act cooperatively in the 60mer. APRIL has no flap sequence 98 and, therefore, theoretically cannot be incor porated into a BAFF 60mer; if APRIL were incorporated it would most likely lead to 60mer dissociation. A better understanding of the relative proportions and activity of BAFF-APRIL homotrimers and heterotrimers might redirect therapeut ic targeting of the BAFF/APRIL system.
Conclusions
The approval of BAFF inhibition as the first targeted therapy for SLE is a major advance in the treatment of this disease, and confirms a role for BAFF in the patho genesis of SLE. However, the diversity of SLE manifesta tions and the monetary cost of biologic therapy might restrict the generalized use of antiBAFF biologic agents in the treatment of SLE. The role of the BAFF/APRIL system in the pathogenesis of SLE needs to be more com pletely understood in order to improve stratification of patients with SLE for effective antiBAFF therapy. Studies of clinical subsets of patients who overexpress BAFF, but who were previously excluded from clinical trials, are particularly needed. Novel data suggest the potential for various approaches to target the BAFF/APRIL system in patients with SLE, such as targeting BAFF 60mers,
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